Mayur Somaiya
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Mayur Ian Somaiya is currently Chief Financial Officer at NewAmsterdam Pharma Co. NV since 2023.
Former roles include Managing Director & Senior Research Analyst at Piper Sandler & Co. (2010–2013), Managing Director at Thomas Weisel Partners LLC (2003–2009), Managing Director & Senior Analyst at Nomura Securities International, Inc. (2013–2016), Managing Director & Analyst at BMO Capital Markets Corp.
(2016–2018), Managing Director at Piper Sandler Cos., Analyst at Prudential Securities (1997–1999), Senior Analyst at Morgan Stanley & Co. LLC (2000–2002), Consultant at Carson Group, Inc. (New York) (1996–1997), Chief Financial Officer at TCR² Therapeutics, Inc. (2018–2021), and Chief Financial & Business Officer at Elucida Oncology, Inc. (2021–2023).
Education includes an undergraduate degree from New York University, conferred in 1995.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.01.2026 | 58’382 ( 0.05% ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Finanzdirektor/CFO | 23.10.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
Elucida Oncology, Inc.
Elucida Oncology, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which focuses on clinical research and development | Finanzdirektor/CFO | 01.07.2023 |
| TCR2 THERAPEUTICS INC. | Finanzdirektor/CFO | 10.12.2021 |
BMO Capital Markets Corp. (Broker)
BMO Capital Markets Corp. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01.04.2018 |
Nomura Securities International, Inc.
Nomura Securities International, Inc. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01.01.2016 |
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 31.10.2013 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Prudential Securities
Prudential Securities Investment Banks/BrokersFinance Provides brokerage services | Finance |
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Thomas Weisel Partners LLC
Thomas Weisel Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Carson Group, Inc. (New York)
Carson Group, Inc. (New York) Investment ManagersFinance Provides financial advisory and investment services | Finance |
Nomura Securities International, Inc.
Nomura Securities International, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BMO Capital Markets Corp. (Broker)
BMO Capital Markets Corp. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
Elucida Oncology, Inc.
Elucida Oncology, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which focuses on clinical research and development | Health Technology |
Piper Sandler Cos.
Piper Sandler Cos. Investment Banks/BrokersFinance Provides investment banking and financial services | Finance |
NewAmsterdam Pharma Co. NV
NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen